These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 392183)

  • 61. Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function.
    Gao P; Scheibel S; D'Amour P; John MR; Rao SD; Schmidt-Gayk H; Cantor TL
    J Bone Miner Res; 2001 Apr; 16(4):605-14. PubMed ID: 11315988
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Parathyroid hormone metabolism and its potential as a uremic toxin.
    Slatopolsky E; Martin K; Hruska K
    Am J Physiol; 1980 Jul; 239(1):F1-12. PubMed ID: 6994509
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Results of parathyroidectomy for autonomous hyperparathyroidism.
    Swanson MR; Biggers JA; Remmers AR; Sarles HE; Nelson RM; Fish JC
    Arch Intern Med; 1979 Sep; 139(9):989-91. PubMed ID: 475537
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats.
    Cozzolino M; Dusso AS; Liapis H; Finch J; Lu Y; Burke SK; Slatopolsky E
    J Am Soc Nephrol; 2002 Sep; 13(9):2299-308. PubMed ID: 12191974
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Surgical management of renal hyperparathyroidism].
    Lorenz K; Sekulla C; Dralle H
    Zentralbl Chir; 2013 Dec; 138 Suppl 2():e47-54. PubMed ID: 21344367
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Total parathyroidectomy for treatment of renal osteodystrophy caused by autonomous hyperparathyroidism.
    Marks C
    Am Surg; 1973 Sep; 39(9):509-13. PubMed ID: 4725806
    [No Abstract]   [Full Text] [Related]  

  • 67. Comparison of different parathyroid hormone radioimmunoassays in uremic patients with secondary hyperparathyroidism.
    Togashi K; Takahashi N; Ando K; Tsukamoto Y; Marumo F
    Int J Artif Organs; 1990 Feb; 13(2):77-82. PubMed ID: 2347659
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The evolution of assays for parathyroid hormone.
    Goodman WG
    Semin Dial; 2005; 18(4):296-301. PubMed ID: 16076352
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia.
    Quarles LD; Lobaugh B; Murphy G
    J Clin Endocrinol Metab; 1992 Jul; 75(1):145-50. PubMed ID: 1619003
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Commentary.
    Hruska K
    Clin Chem; 2009 Sep; 55(9):1740-1. PubMed ID: 19717660
    [No Abstract]   [Full Text] [Related]  

  • 71. Parathyroid hormone and uremic neurotoxicity: an unproven association.
    Arieff AI; Armstrong DK
    Contrib Nephrol; 1980; 20():56-66. PubMed ID: 6995013
    [No Abstract]   [Full Text] [Related]  

  • 72. Adynamic bone disease: from bone to vessels in chronic kidney disease.
    Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ
    Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Suppression of secondary hyperparathyroidism in uraemia: acute and chronic studies.
    Muirhead N; Catto GR; Edward N; Adami S; Manning RM; O'Riordan JL
    Br Med J (Clin Res Ed); 1984 Jan; 288(6412):177-9. PubMed ID: 6419845
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of calcium and phosphorus on patients maintained on dialysis.
    Goldsmith RS; Arnaud CD; Johnson WJ
    Kidney Int Suppl; 1975 Jan; (2):118-22. PubMed ID: 1099298
    [No Abstract]   [Full Text] [Related]  

  • 75. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.
    Román-García P; Carrillo-López N; Cannata-Andía JB
    J Ren Care; 2009 Mar; 35 Suppl 1():34-8. PubMed ID: 19222729
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mineral and bone disorders in patients on dialysis: physiology and clinical consequences.
    McCarley PB; Arjomand M
    Nephrol Nurs J; 2008; 35(1):59-64. PubMed ID: 18372764
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Secondary hyperparathyroidism in chronic renal failure.
    Wills MR; Savory J
    Ann Clin Lab Sci; 1981; 11(3):252-61. PubMed ID: 6264838
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Emerging Association Between Parathyroid Hormone and Anemia in Hemodialysis Patients.
    Tanaka M; Komaba H; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):242-245. PubMed ID: 29767854
    [TBL] [Abstract][Full Text] [Related]  

  • 79. PTH and bone markers of renal osteodystrophy in predialysis chronic renal failure.
    Coen G; Mazzaferro S; Ballanti P; Bonucci E
    J Endocrinol Invest; 1992; 15(9 Suppl 6):129-33. PubMed ID: 1300330
    [No Abstract]   [Full Text] [Related]  

  • 80. Osteocytes in chronic uremia. Differential count of osteocytes in human femoral bone.
    Krempien B; Geiger G; Ritz E; Büttner S
    Virchows Arch A Pathol Pathol Anat; 1973; 360(1):1-9. PubMed ID: 4199228
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.